Latest & greatest articles for adalimumab

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adalimumab or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adalimumab and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for adalimumab

121. Efficacy and safety of adalimumab for the treatment of peripheral arthritis in spondyloarthritis patients without ankylosing spondylitis or psoriatic arthritis

Efficacy and safety of adalimumab for the treatment of peripheral arthritis in spondyloarthritis patients without ankylosing spondylitis or psoriatic arthritis 23139265 2013 10 04 2013 11 26 2015 11 19 1468-2060 72 11 2013 Nov Annals of the rheumatic diseases Ann. Rheum. Dis. Efficacy and safety of adalimumab for the treatment of peripheral arthritis in spondyloarthritis patients without ankylosing spondylitis or psoriatic arthritis. 1793-9 10.1136/annrheumdis-2012-202245 To evaluate (...) the efficacy and safety of adalimumab in patients with peripheral spondyloarthritis (SpA) not fulfilling the criteria for ankylosing spondylitis (AS) or psoriatic arthritis (PsA). 40 patients with active peripheral SpA fulfilling the European Spondyloarthropathy Study Group or Amor criteria but not the criteria for AS or PsA were included in a randomised, double-blind, placebo-controlled clinical trial. Patients were treated 1 : 1 with adalimumab or placebo for 12 weeks, followed by an open label extension

EvidenceUpdates2012

122. Adalimumab for the treatment of moderate to severe ulcerative colitis (terminated appraisal) (TA262)

Adalimumab for the treatment of moderate to severe ulcerative colitis (terminated appraisal) (TA262) Adalimumab for the treatment of moderate to severe ulcerative colitis | Guidance and guidelines | NICE Adalimumab for the treatment of moderate to severe ulcerative colitis Technology appraisal guidance [TA262] Published date: 25 July 2012 Guidance . Explore Guidance app Copyright © 2017 National Institute for Health and Care Excellence. All rights reserved.

National Institute for Health and Clinical Excellence - Technology Appraisals2012

123. Adalimumab (Humira) - in combination with methotrexate for the treatment of active polyarticular juvenile idiopathic arthritis, in children and adolescents aged 4 to 17 years

Adalimumab (Humira) - in combination with methotrexate for the treatment of active polyarticular juvenile idiopathic arthritis, in children and adolescents aged 4 to 17 years Published 07 November 2011 1 adalimumab (Humira®), 40mg solution for injection in pre-filled syringe or pen, 40mg/0.8ml solution for injection vial for paediatric use (No: 738/11) Abbott Laboratories 07 October 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS (...) Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following an abbreviated submission adalimumab (Humira®) solution for injection is accepted for restricted use within NHS Scotland. Indication under review: in combination with methotrexate for the treatment of active polyarticular juvenile idiopathic arthritis, in children and adolescents aged 4 to 17 years who have had an inadequate response to one or more disease

Scottish Medicines Consortium2011

124. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial 21209123 2011 05 11 2011 07 14 2015 11 19 1468-3288 60 6 2011 Jun Gut Gut Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. 780-7 10.1136/gut.2010.221127 The aim of this study was to assess the efficacy and safety of adalimumab (ADA), a recombinant human monoclonal (...) Hanauer Stephen S Schreiber Stefan S Panaccione Remo R Fedorak Richard N RN Tighe Mary Beth MB Huang Bidan B Kampman Wendy W Lazar Andreas A Thakkar Roopal R eng ClinicalTrials.gov NCT00385736 Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't 2011 01 05 England Gut 2985108R 0017-5749 0 Antibodies, Monoclonal 0 Antibodies, Monoclonal, Humanized 0 Gastrointestinal Agents 0 Tumor Necrosis Factor-alpha FYS6T7F842 Adalimumab AIM IM Inflamm Bowel Dis. 2012 Apr;18

EvidenceUpdates2011

125. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation Journals Library An error has occurred in processing the XML document An error occurred

NIHR HTA programme2011

126. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation

Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose

NIHR HTA programme2011

127. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-a) inhibitors, adalimumab and infliximab, for Crohn?s disease

A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-a) inhibitors, adalimumab and infliximab, for Crohn?s disease A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-a) inhibitors, adalimumab and infliximab, for Crohn's disease Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry

NIHR HTA programme2011

128. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation

Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation Rodgers M, Epstein D, Bojke L, Yang H, Craig D, Fonseca T, Myers L, Bruce I, Chalmers R, Bujkiewicz S, Lai M, Cooper N, Abrams (...) K, Spiegelhalter D, Sutton A, Sculpher M, Woolacott N Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Rodgers M, Epstein D, Bojke L, Yang H, Craig D, Fonseca T, Myers L, Bruce I, Chalmers R, Bujkiewicz S, Lai M, Cooper N, Abrams K, Spiegelhalter D, Sutton A, Sculpher M, Woolacott N. Etanercept, infliximab and adalimumab for the treatment

Health Technology Assessment (HTA) Database.2011

129. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor: a systematic review and economic evaluation

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor: a systematic review and economic evaluation Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor: a systematic review and economic evaluation Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF (...) inhibitor: a systematic review and economic evaluation Malottki K, Barton P, Tsourapas A, Uthman AO, Liu Z, Routh K, Connock M, Jobanputra P, Moore D, Fry-Smith A, Chen YF Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Malottki K, Barton P, Tsourapas A, Uthman AO, Liu Z, Routh K, Connock M, Jobanputra P, Moore D, Fry-Smith A, Chen YF. Adalimumab

Health Technology Assessment (HTA) Database.2011

130. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-a) inhibitors, adalimumab and infliximab, for CrohnÔ??s disease

A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-a) inhibitors, adalimumab and infliximab, for CrohnÔ??s disease A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-a) inhibitors, adalimumab and infliximab, for Crohn's disease A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-a) inhibitors, adalimumab and infliximab, for Crohn's disease Dretzke J, Edlin R, Round J (...) , Connock M, Hulme C, Czeczot J, Fry-Smith A, McCabe C, Meads C Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Dretzke J, Edlin R, Round J, Connock M, Hulme C, Czeczot J, Fry-Smith A, McCabe C, Meads C. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-a) inhibitors, adalimumab and infliximab, for Crohn's

Health Technology Assessment (HTA) Database.2011

131. Adalimumab in severe and acute sciatica: A multicentre, randomised, double-blind, placebo-controlled trial

Adalimumab in severe and acute sciatica: A multicentre, randomised, double-blind, placebo-controlled trial 20506391 2010 08 12 2010 09 03 2015 11 19 1529-0131 62 8 2010 Aug Arthritis and rheumatism Arthritis Rheum. Adalimumab in severe and acute sciatica: a multicenter, randomized, double-blind, placebo-controlled trial. 2339-46 10.1002/art.27499 Based on several experimental results and on a preliminary study, a trial was undertaken to assess the efficacy of adalimumab, a tumor necrosis factor (...) alpha inhibitor, in patients with radicular pain due to lumbar disc herniation. A multicenter, double-blind, randomized controlled trial was conducted between May 2005 and December 2007 in Switzerland. Patients with acute (duration of <12 weeks) and severe (Oswestry Disability Index score of >50) radicular leg pain and imaging-confirmed lumbar disc herniation were randomized to receive as adjuvant therapy either 2 subcutaneous injections of adalimumab (40 mg) at 7-day intervals or matching placebo

EvidenceUpdates2010

132. Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial

Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial 19741011 2009 10 19 2009 12 14 2016 11 25 1462-0332 48 11 2009 Nov Rheumatology (Oxford, England) Rheumatology (Oxford) Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. 1429-34 10.1093 (...) /rheumatology/kep261 In early and active RA despite MTX, continuous treatment with TNF blockers in combination with MTX is recommended. To compare this strategy with an initial combination of MTX and adalimumab (ADA) given for 3 months and then adjusted based on the disease activity status. Prospective unblinded randomized multicentre controlled 1-year trial in which 65 patients with early (<6 months) and active [disease activity score (DAS28(ESR)) >5.1] RA were assigned to Group 1 (32 patients): MTX (0.3

EvidenceUpdates2010

133. A systematic review and meta-analysis of the efficacy and safety of adalimumab for treating rheumatoid arthritis

A systematic review and meta-analysis of the efficacy and safety of adalimumab for treating rheumatoid arthritis A systematic review and meta-analysis of the efficacy and safety of adalimumab for treating rheumatoid arthritis A systematic review and meta-analysis of the efficacy and safety of adalimumab for treating rheumatoid arthritis Wiens A, Correr CJ, Venson R, Otuki MF, Pontarolo R CRD summary This generally well-conducted review concluded that adalimumab was more effective than placebo (...) for patients with rheumatoid arthritis, but that adverse events need careful attention. The authors' conclusions appear appropriate, but the longer term results were based on only two trials, one of which had a markedly different patient group, so this analysis may be less reliable. Authors' objectives To evaluate the efficacy and safety of adalimumab for the treatment of rheumatoid arthritis. Searching MEDLINE, EMBASE, the Cochrane Library, SCIELO, LILACS and International Pharmaceutical Abstracts were

DARE.2010

134. Humira (Adalimumab) (Abbott Laboratories) for treatment of pediatric crohn disease

Humira (Adalimumab) (Abbott Laboratories) for treatment of pediatric crohn disease Humira (Adalimumab) (Abbott Laboratories) for treatment of pediatric crohn disease Humira (Adalimumab) (Abbott Laboratories) for treatment of pediatric crohn disease Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Humira (Adalimumab) (Abbott Laboratories) for treatment

Health Technology Assessment (HTA) Database.2010

135. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (TA195)

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (TA195) Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor | Guidance and guidelines | NICE Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor Technology appraisal guidance [TA195 (...) ] Published date: 25 August 2010 Share Guidance on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), rituximab (MabThera) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried other disease-modifying antirheumatic drugs (DMARDs) but cannot tolerate them or they haven’t worked well enough. The recommendations also apply to biosimilar products of these technologies that have a marketing authorisation allowing the use of the biosimilar for the same

National Institute for Health and Clinical Excellence - Technology Appraisals2010

136. Infliximab (review) and adalimumab for the treatment of Crohn's disease (TA187)

Infliximab (review) and adalimumab for the treatment of Crohn's disease (TA187) Infliximab and adalimumab for the treatment of Crohn's disease | Guidance and guidelines | NICE Infliximab and adalimumab for the treatment of Crohn's disease Technology appraisal guidance [TA187] Published date: 19 May 2010 Share Guidance on infliximab (Remicade) and adalimumab (Humira) for treating severe active Crohn's disease in adults. The recommendations also apply to biosimilar products of the technologies

National Institute for Health and Clinical Excellence - Technology Appraisals2010

137. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (TA199)

Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (TA199) Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis | Guidance and guidelines | NICE Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis Technology appraisal guidance [TA199] Published date: 25 August 2010 Share Guidance on etanercept (Enbrel), infliximab (Remicade) and adalimumab (Humira) for treating active and progressive psoriatic arthritis in adults (...) . The recommendations also apply to biosimilar products of these technologies that have a marketing authorisation allowing the use of the biosimilar for the same indication. This guidance replaces NICE technology appraisal guidance on: etanercept and infliximab for the treatment of psoriatic arthritis (TA104) and adalimumab for the treatment of psoriatic arthritis (TA125). Guidance development process Next review date: This guidance will be reviewed if there is new evidence. Your responsibility The recommendations

National Institute for Health and Clinical Excellence - Technology Appraisals2010

139. Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab

Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab Ma C, Panaccione R, Heitman SJ, Devlin SM, Ghosh S, Kaplan GG CRD summary The review concluded that adalimumab was an efficacious therapy for Crohn’s disease patients (...) who discontinued infliximab. Given the lack of quality assessment and other methodological weaknesses, the reliability of the authors’ conclusions is uncertain. Authors' objectives To assess the efficacy of adalimumab in Crohn’s disease patients who are infliximab primary or secondary nonresponders. Searching EMBASE and MEDLINE were searched between 1966 and May 2009 for articles in any language. Search terms were reported. Conference abstracts from American Gastroenterological Association (2006

DARE.2009

140. Adalimumab for the treatment of psoriasis

Adalimumab for the treatment of psoriasis Adalimumab for the treatment of psoriasis Adalimumab for the treatment of psoriasis Turner D, Picot J, Cooper K, Loveman E Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Turner D, Picot J, Cooper K, Loveman E. Adalimumab for the treatment of psoriasis. Health Technology Assessment 2009; 13 (Suppl (...) 2 Article 7): 49-54 Final publication URL Additional data URL Indexing Status Subject indexing assigned by NLM MeSH Adalimumab; Anti-Inflammatory Agents /economics /therapeutic use; Antibodies, Monoclonal /economics /therapeutic use; Antibodies, Monoclonal, Humanized; Cost-Benefit Analysiss; Psoriasis /drug therapy; Quality of Life; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic Language Published English Country of organisation England English summary An English language

Health Technology Assessment (HTA) Database.2009